RegenHU
Provider of advanced bioprinting platforms, including hardware (R-GEN series) and software (SHAPER), for tissue engineering, drug discovery, and personalized medicine.
- CEO / Founder
- Simon MacKenzie
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $2.6M
- Latest Round
- Grant
- Key Investors
- Nivalis Group (Primary Backer), Eurostars Programme, Venture Kick
Technology & Products
Key Products
RegenHU offers 3D bioprinting solutions, including hardware (R-GEN series) and software (SHAPER), for tissue engineering, drug discovery, and personalized medicine.
Technological Advantage
The company's key advantage is its multi-material and multi-technology platforms that can be customized for specific research needs. This versatility allows for the precise fabrication of complex biological structures, accelerating R&D in tissue engineering, drug screening, and personalized medicine.
Patent position
RegenHU has filed 10 patent families across all years, compared with 51 for Aspect Biosystems. AMPulse analysis
- Filing momentum
- 0 families filed 2022–2024, 2 in 2019–2021
- Filed in
- WO 50%EP 30%US 30%JP 10%
- Named competitors, AM patent families
- Aspect Biosystems 51
10 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.
Differentiation
Value Proposition
To enable researchers and clinicians to achieve their goals in regenerative medicine and drug discovery through cutting-edge, customizable, and user-friendly bioprinting technologies that deliver accuracy and repeatability.
How They Differentiate
RegenHU differentiates through its high-precision, modular, and complete bioprinting solutions (hardware, software, and services). Its strong European presence and reputation for Swiss engineering quality set it apart. The company focuses on providing a versatile platform adaptable to a wide range of research applications.
Market & Competition
Target Customers
Biotech, pharmaceutical, cosmetics, and MedTech industries, as well as leading universities and research institutions.
Industry Verticals
Biotechnology, Pharmaceutical, Cosmetics, Medical Research
Competitors
Aspect Biosystems, 3D Biotek, VoxCell BioInnovation, InSphero
Growth & Milestones
Growth Metrics
Privately held, specific growth metrics are not public. The company reports a growing global partnership network and instrument installation in 38 countries.
Major Milestones
2007: Company founded by Marc Thurner., 2011: Secured backing from the Nivalis Group., 2019: Simon MacKenzie appointed as CEO., Launch of the next-generation R-GEN bioprinter series and SHAPER software., Expansion with an office in the United States., 2022: Granted new patents for advanced bioprinting technology.
Notable Customers
Rice University (Biomaterials Lab)
AM patents
AM-relevant patents linked to this company.
- Patents
- 13
- Granted
- 2
- Families
- 10
Leading domains: process (13), equipment (12), application (5)
Filings by year: 2020: 2 · 2017: 6 · 2015: 5
- CARTRIDGE HAVING COMPOSITE MATERIAL2016142323 · WO
- TEMPERATURE-REGULATED ADDITIVE MANUFACTURING2022090321 · WO
- CARTRIDGE WITH COMPOSITE MATERIAL03800051 · EP
- TISSUE SUBSTITUTE PRINTING20200001498 · US
- CARRIER UNIT FOR AN ADDITIVE MANUFACTURING DEVICE2022090327 · WO
Funding rounds
- Grant$0.4M2021-01-01Lead: European Union
- Grant$1.9M2020-01-01Lead: European Union
- Grant$0.3M2019-01-01Lead: European Union
- Seed$0.1M2010-11-01Lead: Venture Kick